The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.
Using genotype and blood plasma protein information for thousands of healthy individuals, researchers documented variants influencing plasma protein levels.
The parties will use Somalogic's SomaScan platform to investigate the ability of protein measurements to affect patient care in a variety of clinical areas.
The company aims to sell its clinical products not as discrete tests but as sets of "insights" derived from patient proteomic data collected using the platform.
Chinese healthcare firm iCarbonX, which made a $161 million investment in the firm last year, was joined by Nan Fung Life Sciences and Madryn Asset Management.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
The funds come from an equity investment by Chinese health firm iCarbonX announced at the beginning of the year as part of a partnership between the companies.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.
A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.
In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."
In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.